Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 5:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Influenza a Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

CSL H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations

NCT00943488
View directory record Official record
Conditions
Influenza
Interventions
Inactivated H1N1 Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
4
States / cities
Iowa City, Iowa • Cincinnati, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Jun 10, 2026, 5:00 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults

NCT05827068
View directory record Official record
Conditions
Seasonal Influenza
Interventions
mRNA-1011.1, mRNA-1011.2, mRNA-1012.1, mRNA-1010, mRNA-1010.2, mRNA-1010.3
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years to 75 Years
Enrollment
698 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
22
States / cities
Lakewood, California • Long Beach, California • Fort Collins, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Jun 10, 2026, 5:00 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Oseltamivir Treatment for Children Less Than 24 Months of Age With Influenza

NCT00391768
View directory record Official record
Conditions
Influenza
Interventions
oseltamivir (Tamiflu®)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 23 Months
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
29
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2013 · Synced Jun 10, 2026, 5:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years

NCT03275389
View directory record Official record
Conditions
Influenza, Human
Interventions
D-SUIV cH8/1N1+AS03, D-SUIV cH5/1N1+AS03, D-SUIV cH11/1N1+AS03, D-SUIV cH8/1N1+AS01, D-SUIV cH5/1N1+AS01, D-SUIV cH11/1N1+AS01, D-SUIV cH8/1N1, D-SUIV cH5/1N1, D-SUIV cH11/1N1, Placebo, Fluarix Quadrivalent
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 39 Years
Enrollment
470 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
5
States / cities
South Miami, Florida • Wichita, Kansas • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Jun 10, 2026, 5:00 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children

NCT00391391
View directory record Official record
Conditions
Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Interventions
Split, Inactivated, Trivalent Influenza Vaccine, Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)
Biological
Lead sponsor
Sanofi
Industry
Eligibility
6 Months to 8 Years
Enrollment
520 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
19
States / cities
Harrisburg, Arkansas • Little Rock, Arkansas • Trumann, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2011 · Synced Jun 10, 2026, 5:00 PM EDT
Completed Phase 4 Interventional Results available

Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents

NCT02250274
View directory record Official record
Conditions
Immune Response to Influenza Vaccine, Influenza A Virus Infection, Influenza B Virus Infection
Interventions
LAIV, IIV
Biological
Lead sponsor
Marshfield Clinic Research Foundation
Other
Eligibility
5 Years to 17 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Marshfield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Jun 10, 2026, 5:00 PM EDT
Completed No phase listed Observational

Clinical Evaluation of QFlu Combo Test

NCT01506583
View directory record Official record
Conditions
Cough, Myalgia, Nasal Obstruction, Sore Throat, Headache, Fatigue, Fever
Interventions
Not listed
Lead sponsor
Cellex, Inc.
Industry
Eligibility
Not listed
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Birmingham, Alabama • Chicago, Illinois • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Jun 10, 2026, 5:00 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications

NCT03381196
View directory record Official record
Conditions
Influenza A
Interventions
Pimodivir 600 mg, Placebo, SOC Treatment
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
13 Years to 85 Years
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
140
States / cities
Birmingham, Alabama • Scottsboro, Alabama • California City, California + 105 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Jun 10, 2026, 5:00 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Digital Storytelling to Reduce Pediatric Influenza Vaccination Disparities

NCT06274359
View directory record Official record
Conditions
Influenza
Interventions
Digital storytelling
Behavioral
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Jun 10, 2026, 5:00 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Study of the Protective Effect of an Injectable Influenza Vaccine Against Influenza Illness in Adults Under 50 y.o.

NCT00216242
View directory record Official record
Conditions
Influenza
Interventions
Influenza virus vaccine (Fluviral), Saline placebo
Biological
Lead sponsor
ID Biomedical Corporation, Quebec
Industry
Eligibility
18 Years to 49 Years
Enrollment
7,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
43
States / cities
Sacramento, California • San Francisco, California • Denver, Colorado + 34 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2006 · Synced Jun 10, 2026, 5:00 PM EDT
Completed No phase listed Observational

Immune Response to Seasonal Influenza Vaccine in HIV Infected Individuals

NCT01381029
View directory record Official record
Conditions
Influenza, Human, Human Immunodeficiency Virus I Infection
Interventions
Not listed
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 99 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Jun 10, 2026, 5:00 PM EDT
Completed No phase listed Observational

Collection and Extraction of Respiratory Specimens

NCT01083511
View directory record Official record
Conditions
Influenza
Interventions
Not listed
Lead sponsor
QIAGEN Gaithersburg, Inc
Industry
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Tucson, Arizona • Chapel Hill, North Carolina • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Jun 10, 2026, 5:00 PM EDT
Completed No phase listed Observational

Evaluation of the Labcorp COVID-19+Flu+RSV Test Home Collection Kit

NCT06008457
View directory record Official record
Conditions
COVID-19 Respiratory Infection, Influenza A, Influenza Type B, RSV Infection
Interventions
Labcorp COVID-19+Flu+RSV Test Home Collection Kit
Device
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
2 Years to 89 Years
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Jun 10, 2026, 5:00 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults

NCT05333289
View directory record Official record
Conditions
Seasonal Influenza
Interventions
mRNA-1030, mRNA-1020, mRNA-1010, Active Comparator
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
572 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
15
States / cities
Phoenix, Arizona • Coral Gables, Florida • Jupiter, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Jun 10, 2026, 5:00 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

H5 Booster After a Two Dose Schedule

NCT00240968
View directory record Official record
Conditions
Influenza
Interventions
Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
3
States / cities
Torrance, California • Baltimore, Maryland • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 15, 2013 · Synced Jun 10, 2026, 5:00 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Immunologic Response to FluMist vs. Flucelvax

NCT03982069
View directory record Official record
Conditions
Influenza, Human, Immune Response
Interventions
FluMist live attenuated influenza vaccine, Flucelvax inactivated influenza vaccine
Biological
Lead sponsor
Richard Zimmerman MD
Other
Eligibility
4 Years to 21 Years
Enrollment
465 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Jun 10, 2026, 5:00 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults

NCT03301051
View directory record Official record
Conditions
Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections, Influenza
Interventions
Quadrivalent VLP Vaccine, Placebo
Biological
Lead sponsor
Medicago
Industry
Eligibility
18 Years to 64 Years
Enrollment
10,160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
29
States / cities
Mobile, Alabama • Anaheim, California • Milford, Connecticut + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Jun 10, 2026, 5:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years

NCT01676402
View directory record Official record
Conditions
Influenza
Interventions
Seasonal Influenza DNA vaccine, TIV
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
316 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
4
States / cities
Stanford, California • Iowa City, Iowa • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Jun 10, 2026, 5:00 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Prospective Study to Evaluate the Safety of a New Monovalent Intranasal Influenza Vaccine

NCT00873912
View directory record Official record
Conditions
Healthy
Interventions
Monovalent influenza virus vaccine, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
3
States / cities
Daytona Beach, Florida • Portland, Oregon • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2011 · Synced Jun 10, 2026, 5:00 PM EDT
Completed Phase 2 Interventional

Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects

NCT00979251
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir Phosphate, ADS-8902
Drug
Lead sponsor
Adamas Pharmaceuticals, Inc.
Industry
Eligibility
1 Year to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
16
States / cities
San Francisco, California • Hollywood, Florida • Miramar, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2014 · Synced Jun 10, 2026, 5:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults

NCT02624219
View directory record Official record
Conditions
Avian Influenza, Influenza
Interventions
AS03, MF59 adjuvant, Monovalent Influenza A/H5N8 vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years to 64 Years
Enrollment
276 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
4
States / cities
Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Jun 10, 2026, 5:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Placebo-controlled,Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Adults

NCT02350751
View directory record Official record
Conditions
Influenza
Interventions
MEDI8852, Placebo
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2015 · Synced Jun 10, 2026, 5:00 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study to Evaluate the Effectiveness of FluMist Vaccination in a School-Based Intervention Program

NCT00192218
View directory record Official record
Conditions
Influenza
Interventions
FluMist
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
5 Years to 17 Years
Enrollment
3,022 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
2
States / cities
Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 21, 2008 · Synced Jun 10, 2026, 5:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone

NCT01498718
View directory record Official record
Conditions
Influenza
Interventions
DNA vaccine, TIV
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
4
States / cities
Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Jun 10, 2026, 5:00 PM EDT